An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.

There was a higher risk of death with the older-generation valves, which investigators attribute to paravalvular leaks.

Much remains to learn about this anatomical finding, seen in about one-third of adults, and how it may affect stroke risk.

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

These data should help reassure those concerned with the risks of educating physicians through live cases at medical meetings ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...

There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...